VAP® Lipid Panel Supports Five Scientific Presentations at the American College of Cardiology 62nd Annual Scientific Session

Comprehensive lipid profile provides accurate lipid subclass measurement for cardiovascular risk identification and prevention research

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Research findings presented at the American College of Cardiology’s Annual Scientific Session (ACC.13) in San Francisco will highlight the critical role of Atherotech Diagnostics Lab’s patented VAP^® Lipid Panel in improving cardiovascular risk stratification in heart disease research and clinical practice.

“Association of Atherogenic Lipoproteins with Long-Term Outcomes among Patients Undergoing Angiography.”

The VAP (Vertical Auto Profile) Lipid Panel is utilized in five independent investigator-initiated scientific presentations at ACC.13: four poster presentations and one oral presentation. Highly respected researchers Peter P. Toth, M.D., Heidi T. May, Ph.D., Mohamed B. Elshazly, M.D., and Arif A. Khokhar, B.M., B.Ch., M.A. (CANTAB), will present the findings during the conference. A complete list of Atherotech-related scientific presentations is available at www.CobblesCorner.com/ACC13.

Dr. Toth, director of preventative cardiology at CGH Medical Center in Sterling, Ill., and member of Atherotech’s Medical Advisory Board, will present two poster presentations on Saturday, March 9, from 3:45-4:30 p.m. in the Expo North building. He will present number 1145-4 “Impact of Lipoprotein Remnants on 12 Year Risk for CHD in the Framingham Offspring Population” and number 1146M-13 “Impact of HDL-C and its Subfractions on Risk for CHD in the Framingham Offspring Population.” Both will be on display throughout the afternoon session from 1:30-4:30 p.m. Toth has authored or coauthored more than 200 publications and is president of the National Lipid Association.

Also presenting posters Saturday afternoon from 3:45-4:30 p.m. in Expo North are Drs. May and Elshazly. Presentation 1145-1 by Dr. May of the Intermountain Medical Center Heart Institute in Murray, Utah, is titled, “Association of Atherogenic Lipoproteins with Long-Term Outcomes among Patients Undergoing Angiography.” Dr. Elshazly of the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins University in Baltimore, will present poster presentation 1145-5 “Patient-Level Discordance in Population Percentiles of the TC/HDL-C ratio, Non-HDL-C, and LDL-C: Insights from the Very Large Database of Lipids Study (VLDL-2).” Both posters will be on display from 1:30-4:30 p.m. during the afternoon session.

On Sunday, March 10, at 8:45 a.m., Dr. Khokhar of Northwest London Hospitals in the United Kingdom, will deliver his oral presentation 919-6 “Triglyceride-Rich Remnant Lipoprotein Cholesterol Predicts Acute Myocardial Infarction in African Americans: The Jackson Heart Study” in Expo West room 2006.

Atherotech will provide conference participants with their own VAP Lipid Panels to demonstrate the importance of accurately identifying cardiovascular disease risk through directly measured LDL and other parameters, leading to personalized treatment and improved heart-health outcomes. Atherotech representatives will be available to discuss the VAP Lipid Panel in booth S2543, and blood draws will be provided to qualified attendees during regular exhibit hours. Because LDL is directly measured, fasting is not required.

Get updates throughout the conference by following the ACC.13 on Twitter via the hashtag #ACC13, and posts from @ACC_2013 and @Atherotech. For information on the VAP Lipid Panel, visit www.Atherotech.com or call 877-901-8510. Health care professionals interested in real cases from the trenches of lipidology may visit www.CobblesCorner.com, Atherotech’s official blog. Atherotech is on Twitter at www.Twitter.com/Atherotech, on Facebook at www.Facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.

To arrange interviews with any of these presenters, or other Atherotech medical experts in attendance at ACC.13 who can provide outside comment on these and other sessions, please call 720-231-9990 or e-mail [e-mail]. Atherotech’s full schedule of science presented at ACC.13 and related materials can be found on www.CobblesCorner.com. All research results are embargoed until the time they are presented during the conference. All times listed are Pacific Time. Please refer to the American College of Cardiology for embargo policies pertaining to presentations at the ACC.13.

About Atherotech Diagnostics Lab & the VAP Lipid Panel

Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech’s proprietary and comprehensive VAP^® Lipid Panel enables clinicians to accurately stratify a patient’s cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP Lipid Panel utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company’s dedication to affordable, comprehensive disease management solutions includes Our Healthy Heart, a patient consultation program and expert lipid management education service to health care providers. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.